Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.
about
Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in micePEGylated Adenoviruses: From Mice to MonkeysOncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic ApplicationsMechanisms of microbubble-facilitated sonoporation for drug and gene delivery.Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccinesEndoplasmic reticulum aminopeptidase-1 functions regulate key aspects of the innate immune responseRecombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic targetAdenovirus-vectored drug-vaccine duo as a rapid-response tool for conferring seamless protection against influenzaVaccine platforms combining circumsporozoite protein and potent immune modulators, rEA or EAT-2, paradoxically result in opposing immune responsesAdenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.Development of adenoviral vector-based mucosal vaccine against influenza.Improving ultrasound gene transfection efficiency by controlling ultrasound excitation of microbubblesTransient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.Induction of shock after intravenous injection of adenovirus vectors: a critical role for platelet-activating factorAdenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo.PDGF-B gene therapy accelerates bone engineering and oral implant osseointegration.Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunityCR1/2 is an important suppressor of Adenovirus-induced innate immune responses and is required for induction of neutralizing antibodiesElectroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developmentsA porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an H5N1 virus disease modelNew adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission.beta-Arrestins modulate Adenovirus-vector-induced innate immune responses: differential regulation by beta-arrestin-1 and beta-arrestin-2.Translating Sleeping Beauty transposition into cellular therapies: victories and challenges.Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse modelNon-viral eNOS gene delivery and transfection with stents for the treatment of restenosis.Delivery of molecules into cells using localized single cell electroporation on ITO micro-electrode based transparent chip.The human adenovirus type 5 E1B 55 kDa protein obstructs inhibition of viral replication by type I interferon in normal human cells.Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectorsSpecies differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirusMyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8(+) T lymphocytes.Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination.Use of DAF-displaying adenovirus vectors reduces induction of transgene- and vector-specific adaptive immune responses in mice.Increasing the efficacy of oncolytic adenovirus vectorsThe role of endosomal escape and mitogen-activated protein kinases in adenoviral activation of the innate immune response.Adenovirus-mediated expression of truncated E2F-1 suppresses tumor growth in vitro and in vivoOptimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity.Transcriptome sequencing and development of an expression microarray platform for liver infection in adenovirus type 5-infected Syrian golden hamsters.Influence of method of systemic administration of adenovirus on virus-mediated toxicity: focus on mortality, virus distribution, and drug metabolism.
P2860
Q21092172-0C69AB6C-DBEE-4A8C-9F4E-5BDA45F48D01Q24635276-106A4A82-5F4D-4BA2-BF74-18C1D8536CE1Q26776553-BB9DC149-C4B5-4EC3-9B63-B5650695D8FFQ26859479-B17F79DF-EDA5-4010-AAAE-56A11663ED23Q27013568-52E86741-4105-4444-86CE-2054067FBEE7Q27310960-8F023184-6501-4308-AA85-AFF0E7DD49D1Q27321063-A0BF906C-5AAF-4371-8795-F51D28CF8C7DQ27333475-61892E81-C14A-4836-A8A6-C112A5300A5AQ28479491-87C51958-5F4F-4216-9F0D-2965D21E5A3DQ28740832-94EC368F-3233-40FA-A028-28E966413915Q30375982-56F8AD17-DA59-49DB-BE68-5781675C3B0BQ30396642-9694E202-381B-457D-AA0F-3A92FA9A1F01Q30430111-60674B76-9CDA-495A-AFBE-46B85079C677Q33382953-0BCB4889-83FD-4A00-82A4-15556C467D65Q33387265-04102712-10BC-4EC1-88A0-CEA629BF110AQ33389860-694B436C-524F-466C-B7D7-7CB62BFBAE91Q33578192-051C26B4-0B79-4908-8F58-ECA6B241324BQ33622711-6F85688B-D4FE-4B31-991B-BF0107519BCDQ33657130-C3BC9531-8E33-40CB-8358-D1D860770B80Q33687979-631691E6-F7A0-4C33-9884-5A45F3AE516FQ33713435-11E08C7B-C66C-4FEB-B281-71206416EB3AQ33778607-04BDD317-EB0D-49B6-B963-1D77B19E8F2FQ33801989-3D25A13D-B91A-4488-96B3-C9B368F3851AQ33915868-A9FB8786-D41A-4D85-9140-C38270C84735Q34127579-9BED6147-6A47-4CDC-A66C-039DCC19CBBFQ34153735-E1818346-8875-4583-9744-C38E93C67C59Q34203043-9388F7CF-02CE-494A-BE65-E635B03AF451Q34295090-D69E73E7-C1C1-439C-A80D-9FC0364E51BFQ34388476-6A77012A-DC52-4BCB-BB77-A448B9A643BEQ34457800-E436044B-22E2-47C6-AA3B-A8ECE7AA9597Q34975214-9AFD2F93-A58E-4AE1-9937-C68ABFA704F3Q35046630-C7D4A9DC-8C89-4D58-9331-FB1A5DCDCABAQ35209044-2E7C6DBE-3C26-404E-B895-1E819B80EF77Q35226117-2B758AFE-B870-41E8-8FE5-B6E4A7AD9E9EQ35261325-FCB073D6-6D29-4B4A-8E61-8D5A728AB1B9Q35462794-46EEB9F8-36A7-4616-AC4A-A530793E1861Q35586632-11286C63-8A15-4B64-A3AE-81C369B41EA8Q35666180-92EF1AAF-91BF-4E1D-B138-6BF5BD7EF253Q36202563-205DA68E-0FAB-4EAE-A84E-0854B05BC9C2Q36395442-8FC8ECA7-7E8A-4B57-911F-0ED128EF6D5E
P2860
Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Adenovirus vector induced inna ...... rapy and vaccine applications.
@ast
Adenovirus vector induced inna ...... rapy and vaccine applications.
@en
Adenovirus vector induced inna ...... rapy and vaccine applications.
@nl
type
label
Adenovirus vector induced inna ...... rapy and vaccine applications.
@ast
Adenovirus vector induced inna ...... rapy and vaccine applications.
@en
Adenovirus vector induced inna ...... rapy and vaccine applications.
@nl
prefLabel
Adenovirus vector induced inna ...... rapy and vaccine applications.
@ast
Adenovirus vector induced inna ...... rapy and vaccine applications.
@en
Adenovirus vector induced inna ...... rapy and vaccine applications.
@nl
P2093
P2860
P1433
P1476
Adenovirus vector induced inna ...... rapy and vaccine applications.
@en
P2093
Andrea Amalfitano
Daniel M Appledorn
Zachary C Hartman
P2860
P356
10.1016/J.VIRUSRES.2007.10.005
P577
2007-11-26T00:00:00Z